Dimerix opens post trial access to DMX-200 for patients with FSGS

Dimerix has announced that patients who complete the ACTION3 Phase 3 trial and its open-label extension may be allowed to continue receiving the investigational candidate DMX-200 through post‑trial access pathways in key territories.